Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors

World Journal of Gastroenterology

Volumn 20, Issue 36, 2014, Pages 12945-12955

  Dongiovanni, Paola ^a,b   Romeo, Stefano ^c,d   Valenti, Luca ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cirrhosis; Fibrogenesis; Genetics; Hepatocellular carcinoma; Liver disease; Nonalcoholic fatty liver disease; Patatin like phospholipase domain containing 3; Single nucleotide polymorphism; Steatosis

Indexed keywords

VERY LOW DENSITY LIPOPROTEIN;

APOLIPOPROTEIN B GENE; ARTICLE; CELL AGING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FATTY LIVER; GENETIC VARIABILITY; HEREDITY; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; IRON OVERLOAD; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 GENE; PATHOGENESIS; RISK FACTOR; STELLATE CELL; TELOMERASE REVERSE TRANSCRIPTASE GENE; ANIMAL; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; LIVER; LIVER NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84927615859     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i36.12945     Document Type: Article

References (120)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750 [PMID: 10072408 DOI: 10.1056/NEJM19990311340 1001]
2. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
4. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, Cariani E, Sangiovanni A, Tommasini M, Rossini A, Bertelli C, Fatta E, Patriarca V, Brescianini S, Stroffolini T. Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis 2005; 35: 27-32 [PMID: 15894495 DOI: 10.1016/ j.bcmd.2005.03.007]
5. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42: 514-521 [PMID: 16044402 DOI: 10.1002/hep.20815]
6. Fracanzani AL, Piperno A, Valenti L, Fraquelli M, Coletti S, Maraschi A, Consonni D, Coviello E, Conte D, Fargion S. Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors. Hepatology 2010; 51: 501-510 [PMID: 20101754 DOI: 10.1002/hep.23333]
7. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391 [PMID: 22326465 DOI: 10.1016/ j.jhep.2011.10.027]
8. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455 [PMID: 10569299 DOI: 10.1016/S0002-9343(99)00271-5]
9. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117 [PMID: 23978719 DOI: 10.1016/j.jhep.2013.08.011]
10. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310 [PMID: 16729298 DOI: 10.1002/hep.21176]
11. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-2467 [PMID: 11513191 DOI: 10.1111/j.1572-0241.2001.04054.x]
12. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224 [PMID: 15664247 DOI: 10.1016/j.jhep.2004.10.005]
13. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel-Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PH, Lund E, Quirós JR, González CA, Sanchez Perez MJ, Navarro C, Dorronsoro M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw KT, Wareham N, Key T, Romieu I, Chuang SC, Murphy N, Boffetta P, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103: 1686-1695 [PMID: 22021666 DOI: 10.1093/jnci/djr395]
14. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
15. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 2013; 108: 222-228 [PMID: 23169288 DOI: 10.1038/ bjc.2012.492]
16. Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol 2012; 57: 663-674 [PMID: 22609306 DOI: 10.1016/ j.jhep.2012.02.035]
17. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012; 55: 1416-1425 [PMID: 22095619 DOI: 10.1002/hep.24794]
18. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850 [PMID: 11473047 DOI: 10.2337/diabetes.50.8.1844]
19. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210 [PMID: 16401483 DOI: 10.1053/j.gastro.2005.11.017]
20. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842 DOI: 10.1053/gast.2002.34168]
21. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45 [PMID: 23703888 DOI: 10.1093/aje/kws448]
22. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]
23. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665 [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183]
24. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661 [PMID: 19834957 DOI: 10.1002/ cncr.24687]
25. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354 [PMID: 12447858 DOI: 10.1053/jhep.2002.36939]
26. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69-S73 [PMID: 14762843 DOI: 10.1002/lt.20033]
27. Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ, Lee YJ, Lee KH, Ahn S. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 2013; 13: 335 [PMID: 23829392 DOI: 10.1186/1471-2407-13-335]
28. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-160 [PMID: 12076877 DOI: 10.1016/S0168-8278(02)00099-5]
29. Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeyama S, Okita K. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39: 391-396 [PMID: 15168253 DOI: 10.1007/s00535-003-1308-3]
30. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978 [PMID: 20209604 DOI: 10.1002/hep.23527]
31. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065]
32. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16: 1436-1441 [PMID: 20333782 DOI: 10.3748/wjg.v16.i12.1436]
33. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33; quiz e50 [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023]
34. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-990 [PMID: 7475591 DOI: 10.1016/S0140-6736(95)91685-7]
35. Valenti L, Fracanzani AL, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol 2009; 31: 359-369 [PMID: 19440711 DOI: 10.1007/s00281-009-0152-9]
36. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496 [PMID: 17487861 DOI: 10.1002/ cncr.22701]
37. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-5187 [PMID: 17876888]
38. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-e522 [PMID: 21914071 DOI: 10.1111/j.1365-2893.2011.01441.x]
39. Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virusrelated cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010; 34: 1630-1636 [PMID: 20975341 DOI: 10.1097/ PAS.0b013e3181f31caa]
40. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013; 28: 848-854 [PMID: 23302015 DOI: 10.1111/jgh.12116]
41. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol 2013; 5: 186-194 [PMID: 24069511 DOI: 10.4251/wjgo.v5.i9.186]
42. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859 [PMID: 19115377 DOI: 10.1002/hep.22734]
43. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008 [PMID: 17700568 DOI: 10.1038/sj.bjc.6603932]
44. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-109 [PMID: 11786965 DOI: 10.1053/jhep.2002.30318]
45. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539 [PMID: 15753540 DOI: 10.1136/ gut.2004.052167]
46. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591 [PMID: 15286738 DOI: 10.1038/nrc1408]
47. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946 [PMID: 20166205 DOI: 10.1002/cncr.24982]
48. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a populationbased cohort study. Am J Gastroenterol 2012; 107: 46-52 [PMID: 22085817 DOI: 10.1038/ajg.2011.384]
49. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013; 108: 1314-1321 [PMID: 23752878 DOI: 10.1038/ajg.2013.160]
50. Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol 2014; 48: 172-177 [PMID: 24402120 DOI: 10.1097/ MCG.0b013e3182a030c4]
51. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-121 [PMID: 18505690 DOI: 10.1053/ j.gastro.2008.03.073]
52. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-1307 [PMID: 20650925 DOI: 10.1136/gut.2009.199661]
53. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208 [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052]
54. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-969 [PMID: 19585655 DOI: 10.1002/hep.23046]
55. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777 [PMID: 17882277 DOI: 10.1038/nrc2222]
56. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 2009; 50: 100-110 [PMID: 19008011 DOI: 10.1016/j.jhep.2008.07.036]
57. Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R, Foti M. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol 2009; 50: 1132-1141 [PMID: 19398230 DOI: 10.1016/j.jhep.2009.01.027]
58. Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology 2011; 152: 2546-2551 [PMID: 21540285 DOI: 10.1210/en.2011-0231]
59. Houglum K, Ramm GA, Crawford DH, Witztum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology 1997; 26: 605-610 [PMID: 9303489 DOI: 10.1002/hep.510260311]
60. Valenti L, Fracanzani AL, Rametta R, Fraquelli M, Soverini G, Pelusi S, Dongiovanni P, Conte D, Fargion S. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol 2012; 57: 1319-1325 [PMID: 22885719 DOI: 10.1016/ j.jhep.2012.07.041]
61. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005; 25: 461-472 [PMID: 16315139 DOI: 10.1055/s-2005-923317]
62. Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Fargion S, Valenti L. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010; 176: 1006-1017 [PMID: 20019189 DOI: 10.2353/amjpath.2010.090249]
63. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 2448-2455 [PMID: 11513189 DOI: 10.1111/j.1572-0241.2001.04052.x]
64. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-187 [PMID: 14752836 DOI: 10.1002/hep.20023]
65. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-1163 [PMID: 10535879 DOI: 10.1016/ S0016-5085(99)70401-4]
66. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010; 138: 905-912 [PMID: 19931264 DOI: 10.1053/j.gastro.2009.11.013]
67. Dongiovanni P, Ruscica M, Rametta R, Recalcati S, Steffani L, Gatti S, Girelli D, Cairo G, Magni P, Fargion S, Valenti L. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol 2013; 182: 2254-2263 [PMID: 23578384 DOI: 10.1016/j.ajpath.2013.02.019]
68. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-1258 [PMID: 17391316 DOI: 10.1111/j.1572-0241.2007.01192.x]
69. Stál P, Hultcrantz R, Möller L, Eriksson LC. The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology 1995; 21: 521-528 [PMID: 7843726 DOI: 10.1016/0270-9139(95)90115-9]
70. Carthew P, Nolan BM, Smith AG, Edwards RE. Iron promotes DEN initiated GST-P foci in rat liver. Carcinogenesis 1997; 18: 599-603 [PMID: 9067562 DOI: 10.1093/carcin/ 18.3.599]
71. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-357 [PMID: 19070395 DOI: 10.1016/ j.jhep.2008.09.011]
72. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920-932 [PMID: 21718726 DOI: 10.1016/j.jhep.2011.05.008]
73. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013; 19: 5219-5238 [PMID: 23394097 DOI: 10.2174/1381612811319999 0381]
74. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-758 [PMID: 20676096 DOI: 10.1038/ng.638]
75. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43: 455-458 [PMID: 21499248 DOI: 10.1038/ng.809]
76. Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43: 797-800 [PMID: 21725309 DOI: 10.1038/ng.876]
77. Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease. Dig Liver Dis 2013; 45: 619-624 [PMID: 23333103 DOI: 10.1016/ j.dld.2012.12.006]
78. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753 [PMID: 19812666 DOI: 10.1038/nature08494]
79. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
80. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520-528 [PMID: 18940312 DOI: 10.1016/j.ajhg.2008.09.012]
81. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715 [PMID: 20034933 DOI: 10.1074/jbc.M109.064501]
82. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA 2010; 107: 7892-7897 [PMID: 20385813 DOI: 10.1073/pnas.1003585107]
83. Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Sta˚hlman M, Taskinen MR, Orho-Melander M, Perman J, Pujia A, Andersson L, Maglio C, Montalcini T, Wiklund O, Borén J, Romeo S. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57: 1276-1282 [PMID: 22878467 DOI: 10.1016/j.jhep.2012.07.030]
84. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217 [PMID: 20373368 DOI: 10.1002/hep.23622]
85. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe J. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95 [PMID: 21254164 DOI: 10.1002/hep.24017]
86. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
87. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42: 21-23 [PMID: 19946271 DOI: 10.1038/ng.488]
88. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, Colombo M, Fargion S. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-799 [PMID: 21319195 DOI: 10.1002/hep.24123]
89. Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C. Impact of patatin-like phospholipase-3 (rs738409 C& gt; G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-69 [PMID: 21488075 DOI: 10.1002/hep.24350]
90. Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi S, Mariani R, Dongiovanni P, Fracanzani AL, Fargion S. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol 2012; 18: 2813-2820 [PMID: 22719190 DOI: 10.3748/wjg.v18.i22.2813]
91. Viganò M, Valenti L, Lampertico P, Facchetti F, Motta BM, D' Ambrosio R, Romagnoli S, Dongiovanni P, Donati B, Fargion S, Colombo M. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013; 58: 1245-1252 [PMID: 23564580 DOI: 10.1002/hep.26445]
92. Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, Sutton A, Nahon P, Moreno C. PNPLA3 (rs738409 C& gt; G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55: 1307-1308 [PMID: 22162034 DOI: 10.1002/ hep.25518]
93. Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011; 53: 1776; author reply 1777 [PMID: 21351112 DOI: 10.1002/hep.24244]
94. Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, Fornasiere E, Bignulin S, Fumolo E, Bignulin E, Pirisi M, Toniutto P. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31: 1137-1143 [PMID: 21745286 DOI: 10.1111/j.1478-3231.2011.02534.x]
95. Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M, Krämer B, Körner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 2011; 6: e27087 [PMID: 22087248 DOI: 10.1371/journal.pone.0027087]
96. Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, Ganne-Carrié N, Beaugrand M, Charnaux N, Trinchet JC, Nahon P. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013; 58: 312-318 [PMID: 23069476 DOI: 10.1016/j.jhep.2012.09.036]
97. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P. Association between the PNPLA3 (rs738409 C& gt; G) variant and hepatocellular carcinoma: Evidence from a metaanalysis of individual participant data. Hepatology 2014; 59: 2170-2177 [PMID: 24114809 DOI: 10.1002/hep.26767]
98. Burza MA, Pirazzi C, Maglio C, Sjöholm K, Mancina RM, Svensson PA, Jacobson P, Adiels M, Baroni MG, Borén J, Ginanni Corradini S, Montalcini T, Sjöström L, Carlsson LM, Romeo S. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 2012; 44: 1037-1041 [PMID: 22704398 DOI: 10.1016/j.dld.2012.05.006]
99. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM. Carriage of the PNPLA3 rs738409 C & gt; G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61: 75-81 [PMID: 24607626 DOI: 10.1016/j.jhep.2014.02.030]
100. Valenti L, Motta BM, Soardo G, Iavarone M, Donati B, Sangiovanni A, Carnelutti A, Dongiovanni P, Rametta R, Bertelli C, Facchetti F, Colombo M, Fargion S, Fracanzani AL. PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. PLoS One 2013; 8: e75982 [PMID: 24155878 DOI: 10.1371/journal. pone.0075982]
101. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog 2013; 52 Suppl 1: E139-E147 [PMID: 23776098 DOI: 10.1002/mc.22057]
102. Lonardo A, Tarugi P, Ballarini G, Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci 1998; 43: 2489-2492 [PMID: 9824140]
103. Bonnefont-Rousselot D, Condat B, Sassolas A, Chebel S, Bittar R, Federspiel MC, Cazals-Hatem D, Bruckert E. Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur J Gastroenterol Hepatol 2009; 21: 104-108 [PMID: 19060634 DOI: 10.1097/MEG.0b013e3282ffd9f8]
104. Cefalù AB, Pirruccello JP, Noto D, Gabriel S, Valenti V, Gupta N, Spina R, Tarugi P, Kathiresan S, Averna MR. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33: 2021-2025 [PMID: 23723369 DOI: 10.1161/ATVBAHA.112.301101]
105. Dwyer J, Li H, Xu D, Liu JP. Transcriptional regulation of telomerase activity: roles of the the Ets transcription factor family. Ann N Y Acad Sci 2007; 1114: 36-47 [PMID: 17986575 DOI: 10.1196/annals.1396.022]
106. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498: 135-146 [PMID: 22381618 DOI: 10.1016/j.gene.2012.01.095]
107. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
108. Chaiteerakij R, Roberts LR. Telomerase mutation: a genetic risk factor for cirrhosis. Hepatology 2011; 53: 1430-1432 [PMID: 21425310 DOI: 10.1002/hep.24304]
109. Calado RT, Regal JA, Kleiner DE, Schrump DS, Peterson NR, Pons V, Chanock SJ, Lansdorp PM, Young NS. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009; 4: e7926 [PMID: 19936245 DOI: 10.1371/journal.pone.0007926]
110. Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, Zago MA, Chanock SJ, Boyer TD, Young NS. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011; 53: 1600-1607 [PMID: 21520173 DOI: 10.1002/ hep.24173]
111. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258 [PMID: 10678830 DOI: 10.1126/science.287.5456.1253]
112. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767 [PMID: 17087938 DOI: 10.1053/j.gastro.2006.09.014]
113. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tu- mors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6026 [PMID: 23530248 DOI: 10.1073/pnas.1303607110]
114. Valenti L, Dongiovanni P, Maggioni M, Motta BM, Rametta R, Milano M, Fargion S, Reggiani P, Fracanzani AL. Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. J Hepatol 2013; 58: 399-401 [PMID: 23000435 DOI: 10.1016/ j.jhep.2012.09.011]
115. Liang J, Yagasaki H, Kamachi Y, Hama A, Matsumoto K, Kato K, Kudo K, Kojima S. Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. Haematologica 2006; 91: 656-658 [PMID: 16627250]
116. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57 [PMID: 20029423 DOI: 10.1038/nrc2772]
117. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005]
118. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101 [PMID: 23803760 DOI: 10.1038/nature12347]
119. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003; 37: 653-664 [PMID: 12601363 DOI: 10.1053/jhep.2003.50097]
120. Devkota S, Turnbaugh PJ. Cancer: An acidic link. Nature 2013; 499: 37-38 [PMID: 23803768 DOI: 10.1038/nature12404]